Latest Innovation News

ECP Emerging Growth Limited reported a modest 2.4% return for FY2025, lagging the ASX Small Ordinaries Index, but is pursuing new strategies including a pre-IPO fund investment and a special dividend to address shareholder value concerns.

PPK Group reports record revenue at Craig International Ballistics and advances lithium sulfur battery technology, while preparing for a CEO transition and focusing on sovereign manufacturing.

MotorCycle Holdings Limited delivered a standout FY2025 with double-digit revenue and profit growth, underpinned by strong market share gains and operational efficiencies.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Hancock & Gore is rebranding as Schoolblazer Limited following its acquisition of Trutex, consolidating its global school uniform operations and targeting over $200 million in revenue by FY27.

Hancock & Gore reports a statutory loss for FY25 amid major acquisitions and strategic transformation, setting sights on $200m revenue by FY27 as it rebrands to Schoolblazer Limited.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.